King's College London

Research portal

Protocol: A prospective, randomised placebo-controlled feasibility trial of Faecal microbiota Transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO)

Research output: Contribution to journalArticle

Blair Merrick, Emily J. Robinson, Catey Bunce, Liz Allen, Karen Bisnauthsing, Chi Chi Izundu, Jordana Bell, Gregory Amos, Manu Shankar-Hari, Anna Goodman, Debbie Shawcross, Simon Goldenberg

Original languageEnglish
JournalBMJ Open
Publication statusAccepted/In press - 3 Apr 2020

King's Authors

Abstract

Introduction: antimicrobial resistance (AMR) is rising, largely due to the indiscriminate use of antimicrobials. The human gut is the largest reservoir of antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the potential to spread these organisms both in the community and hospital settings. Infections with ARB such as extended spectrum betalactamase producing enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE) are more difficult to treat and are associated with an increased morbidity and mortality. Presently there is no effective decolonisation strategy for these ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for decolonisation of ARB from the human gut, however there is significant uncertainty about the feasibility, effectiveness and safety of using this approach. Methods and analysis: prospective, randomised, patient-blinded, placebo-controlled feasibility trial of FMT to eradicate gastrointestinal carriage of ARB. Eighty patients with a recent history of invasive infection secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome measure is consent rate (as a proportion of patients who fulfil inclusion/ exclusion criteria); this will be used to determine if a substantive trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months and 6 months and monitored for adverse events as well as gastrointestinal carriage rates of ARB after intervention. Ethics and dissemination: research ethics approval was obtained by London - City & East Research Ethics Committee (ref 20/LO/0117). Trial results will be published in a peerreviewed journal and presented at international conferences. Trial registration number: ISRCTN registration number 34467677 and EudraCT number 2019-001618-41 protocol version 1.1. (dated 23/02/2020)

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454